{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"BIG-1","nct_id":"NCT02416388","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=big-1-nct02416388. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BIG-1","arms":[{"description":"Idarubicin","label":"R1-IDA","type":"EXPERIMENTAL"},{"description":"Daunorubicin","label":"R1-DAUNO","type":"ACTIVE_COMPARATOR"},{"description":"High dose cytarabine","label":"R2-HDAC","type":"ACTIVE_COMPARATOR"},{"description":"Intermediate dose cytarabine","label":"R2-IDAC","type":"EXPERIMENTAL"},{"description":"Methotrexate and mycophenolic acid","label":"R3-MAC-MTX","type":"ACTIVE_COMPARATOR"},{"description":"Cyclosporine and mycophenolic acid","label":"R3-MAC-MPA","type":"EXPERIMENTAL"},{"description":"Cyclosporine","label":"R3-RIC-CICLO","type":"ACTIVE_COMPARATOR"},{"description":"Cyclosporine and mycophenolic acid","label":"R3-RIC-MPA","type":"EXPERIMENTAL"},{"description":"Intermediate dose cytarabine and vosaroxin","label":"R4-VOS-IDAC","type":"EXPERIMENTAL"},{"description":"Intermediate dose cytarabine alone","label":"R4-IDAC (without VOS)","type":"ACTIVE_COMPARATOR"},{"description":"High dose cytarabine and dexamethasone","label":"R4-DEX-HDAC","type":"EXPERIMENTAL"},{"description":"High dose cytarabine alone","label":"R4-HDAC (without DEX)","type":"ACTIVE_COMPARATOR"},{"description":"Intermediate dose cytarabine and venetoclax","label":"R4-VEN-IDAC","type":"EXPERIMENTAL"},{"description":"Intermediate dose cytarabine alone","label":"R4-IDAC (without VEN)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-01","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":{"count":3100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Idarubicin","otherNames":[],"type":"DRUG"},{"name":"Daunorubicin","otherNames":[],"type":"DRUG"},{"name":"HD Cytarabine","otherNames":[],"type":"DRUG"},{"name":"Cyclosporine","otherNames":[],"type":"DRUG"},{"name":"Methotrexate","otherNames":[],"type":"DRUG"},{"name":"Mycophenolic acid (MPA)","otherNames":[],"type":"DRUG"},{"name":"vosaroxin","otherNames":[],"type":"DRUG"},{"name":"ID cytarabine","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Venetoclax","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-17","lead_sponsor":"University Hospital, Angers","official_title":"Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2025-07-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"3 years"},{"measure":"Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IV","timeFrame":"100 days"},{"measure":"Disease free survival","timeFrame":"18 months"}],"references":[{"citation":"Duployez N, Joudinaud R, Boudry A, Hunault M, Fenwarth L, Tavernier E, Pautas C, Bertoli S, Tavitian S, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carre M, Peterlin P, Gallego-Hernanz MP, Guieze R, Simand C, Turlure P, Huynh A, Lemasle E, Gabellier L, Lambert J, Suarez F, Chraibi S, Sanhes L, Celli-Lebras K, Mineur A, Gardin C, Ifrah N, Vey N, Peffault De Latour R, Rigolot L, Luquet I, Penther D, Itzykson R, Delabesse E, Hamel JF, De Botton S, Pigneux A, Dombret H, Recher C, Preudhomme C, Dumas PY. Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy. Blood. 2026 Jul 30;148(5):598-609. doi: 10.1182/blood.2025032829.","pmid":"42166362","type":"DERIVED"},{"citation":"Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carre M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guieze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socie G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Recher C, Dombret H. Intermediate-Dose Cytarabine as Postinduction AML Therapy. NEJM Evid. 2025 Jul;4(7):EVIDoa2400326. doi: 10.1056/EVIDoa2400326. Epub 2025 Jun 24.","pmid":"40552969","type":"DERIVED"}],"start_date":{"date":"2015-01"},"study_type":"INTERVENTIONAL","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","url":"https://clinicaltrials.gov/study/NCT02416388"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/big-1-nct02416388"}